Endo International Acquires Paladin Labs for $2.7 Billion

Endo International PLC (TSX:ENL,NASDAQ:ENDP), formerly Endo Health Solutions Inc., completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. Endo and Paladin Labs have been combined under a new company incorporated in Ireland named Endo International plc.

Under the terms of the transaction, Paladin Labs shareholders received 1.6331 shares of Endo International plc stock and $1.16 (CAD) in cash for each Paladin Labs share they owned upon closing. In addition, for each Paladin Labs share owned at closing, shareholders of Paladin Labs received one share of Knight Therapeutics Inc., (“Knight Therapeutics”) a newly formed Canadian company that has been separated as part of the transaction. Shareholders of Endo Health Solutions received one share of Endo International plc for each share of Endo Health Solutions Inc. they owned upon closing.

Click here to read the Endo International PLC (TSX:ENL,NASDAQ:ENDP) press release